Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Repros Therapeutics Inc.

Business Wire July 17, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc. (RPRX)

PR Newswire July 17, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX

PR Newswire July 17, 2017

Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA

GlobeNewswire July 17, 2017

Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock

GlobeNewswire May 18, 2017

Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock

GlobeNewswire May 17, 2017

Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results

GlobeNewswire May 9, 2017

Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions

GlobeNewswire April 17, 2017

Repros Names Larry Dillaha, M.D., its Permanent President and CEO

GlobeNewswire April 10, 2017

Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids

GlobeNewswire April 10, 2017

Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results

GlobeNewswire March 31, 2017

Repros Announces New CEO

GlobeNewswire February 2, 2017

FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids

GlobeNewswire January 30, 2017

FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism

GlobeNewswire December 6, 2016

Repros Therapeutics Shares Rally Following Ladenburg Upgrade To Buy, Positive Data

Benzinga.com  November 16, 2016

Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered Orally and Vaginally for the Treatment of Uterine Fibroids

GlobeNewswire November 14, 2016

Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results

GlobeNewswire November 8, 2016

Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities

GlobeNewswire October 5, 2016

FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism

GlobeNewswire September 26, 2016

Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism

GlobeNewswire September 12, 2016